The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The executives leading Hippocratic AI's healthcare sector and international expansion efforts are: ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

I think you have to be on the horse that is Eli Lilly.” Lilly has been making progress in its GLP-1 opportunity and also advancing in other areas like immunology and oncology. The company has ...

Eli Lilly (LLY ... other factors related to earnings estimates, Lilly is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate ...

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Cornell’s (25-4-5, 16-2-4 ECAC ... on March 21 at either 5 p.m. or 8:30 p.m. The game will be streamed live on ESPN+. Eli Fastiff is a senior editor on the 143rd editorial board and a member ...